Perioperative Aspirin Management for Pacemaker Surgery

Introduction to Aspirin Management

• The American College of Cardiology recommends that aspirin should be discontinued 3 days before pacemaker surgery unless the patient has a high thrombotic risk that outweighs bleeding concerns 1
• Aspirin should be restarted as soon as possible after surgery when hemostasis is achieved, typically within 24 hours post-procedure 2

Thrombotic Risk Assessment

• Patients with a coronary stent placed within the last 6 months, a recent stroke/TIA, or at high risk for cardiac events should continue aspirin throughout the perioperative period 2, 3
• Patients with a bare metal stent (BMS) placed within 30 days or a drug-eluting stent (DES) placed within 3-6 months should not discontinue aspirin 2, 4

Bleeding Risk Assessment

• Pacemaker implantation is generally considered a procedure with moderate bleeding risk, and patient-specific factors such as renal dysfunction or prior bleeding events should be considered 1

Aspirin Discontinuation and Resumption

• Aspirin can be discontinued 3 days before surgery in patients without high thrombotic risk, and resumed within 24 hours after procedure once hemostasis is achieved 1, 2
• For urgent/emergent procedures, aspirin should not be discontinued if thrombotic risk outweighs bleeding risk, and additional hemostatic measures should be considered during the procedure 1

Common Pitfalls in Aspirin Management

• Discontinuing aspirin too early (>5 days before surgery) can increase thrombotic risk, and failing to resume aspirin promptly after surgery can also increase risk 1, 2
• Not considering individual patient risk factors for both thrombosis and bleeding, and applying a "one-size-fits-all" approach rather than risk stratification should be avoided 1, 2